Reduction of LDL-cholesterol, total cholesterol, triglycerides, apolipoprotein B & to increase HDL-cholesterol. Management of hyperlipidemias including type IIa, IIb, III, IV & V hyperlipoproteinemias.
May displace other drugs from protein-binding sites. Changes in activity of CYP3A4 isoenzymes. May enhance the effects of anticoagulants. May displace from plasma proteins of other drugs including tolbutamide & other sulfonylurea antidiabetics, phenytoin & furosemide. May alter glucose tolerance w/ antidiabetic drugs. Increased risk of myopathy w/ statins. Nephrotoxicity associated w/ increased ciclosporin conc. Cholestasis w/ raloxifene.